Alexion Pharmaceuticals, Inc., headquartered in Boston, Massachusetts, was a global biopharmaceutical company that developed and sold drugs for patients with life-threatening rare and ultra-rare diseases. Alexion served patients in approximately 50 countries and employed approximately 3,000 people worldwide.
According to its filings, on May 8, 2015, Alexion Pharmaceuticals, Inc. received a subpoena in connection with an investigation by the Enforcement Division of the SEC requesting information related to Alexion’s grant-making activities and compliance with the FCPA in various countries, in particular Japan, Brazil, Turkey and Russia.
In October 2015, Alexion received a request from the DOJ for the voluntary production of documents and other information pertaining to Alexion's compliance with the FCPA. The SEC and DOJ also seek information related to Alexion’s recalls of specific lots of its therapeutic product, Soliris, and related securities disclosures.
In its July 29, 2016 10-Q, Alexion stated that it was cooperating with these investigations.
In its April 27, 2017 10-Q, Alexion noted that the investigations included the country of Colombia, but whether this was added later is unclear.
In its 10-Q filed on May 6, 2020, Alexion disclosed that the DOJ had concluded its investigation and did not intend to pursue further action. Also, the company disclosed that its settlement discussions with the SEC had progressed sufficiently and that it had accrued $25 million in anticipation of resolving the SEC investigation.
On July 2, 2020, the SEC announced an administrative proceeding against Alexion.
